<DOC>
	<DOCNO>NCT00429754</DOCNO>
	<brief_summary>The purpose study investigate whether interaction occur etoposide aprepitant patient testis carcinoma treat standard BEP regimen . Also determine long treatment aprepitant necessary BEP regimen 5 consecutive day .</brief_summary>
	<brief_title>Pharmacokinetic Study Aprepitant BEP Treatment Patients With Testis Carcinoma ( A-BEP )</brief_title>
	<detailed_description>Aprepitant novel , potent selective nonpeptide neurokinin-1 receptor antagonist license 2004 prevention acute delay nausea vomit associate highly emetogenic cancer chemotherapy.More recently indication use aprepitant extend patient moderately emetogenic chemotherapy . Based experience use aprepitant appear rational consider aprepitant part anti-emetic regimen patient treat BEP . There , however , publish data available use aprepitant situation .</detailed_description>
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Aprepitant</mesh_term>
	<mesh_term>Fosaprepitant</mesh_term>
	<criteria>18 75 year age able willing sign Informed Consent Form subject indication treatment BEP regimen subject expect receive least 2 cycle BEP regimen subject able swallow capsule document history sensitivity/idiosyncrasy aprepitant excipients relevant history condition might interfere drug absorption history current abuse drug , alcohol solvent inability understand nature extent trial procedure participation drug trial within 30 day prior first dose febrile illness within 3 day first dose use agent know interfere aprepitant pharmacokinetics abnormal liver renal function</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Nausea vomit use cytostatic drug</keyword>
</DOC>